<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112445795</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112445795</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Therapeutic Oral Sesame Oil Is Ineffectual Against Monocrotaline-Induced Sinusoidal Obstruction Syndrome in Rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Periasamy</surname><given-names>Srinivasan</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112445795">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chien</surname><given-names>Se-Ping</given-names></name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff2-0148607112445795">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liu</surname><given-names>Ming-Yie</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112445795">1</xref>
<xref ref-type="aff" rid="aff3-0148607112445795">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112445795"><label>1</label>National Cheng Kung University Medical College, Tainan, Taiwan</aff>
<aff id="aff2-0148607112445795"><label>2</label>Tainan University of Technology, Tainan, Taiwan</aff>
<aff id="aff3-0148607112445795"><label>3</label>National Cheng Kung University, Tainan, Taiwan</aff>
<author-notes>
<corresp id="corresp1-0148607112445795">Ming-Yie Liu, PhD, Department of Environmental and Occupational Health, National Cheng Kung University Medical College, 138 Sheng-Li Rd, Tainan 70428, Taiwan. Email: <email>myliu@mail.ncku.edu.tw</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>37</volume>
<issue>1</issue>
<fpage>129</fpage>
<lpage>133</lpage>
<history>
<date date-type="received">
<day>21</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>3</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: The chemotherapeutic drug oxaliplatin causes sinusoidal obstruction syndrome (SOS), which is analogous to that of monocrotaline-induced SOS. Sesame oil is a nutrient-rich antioxidant in alternative medicine. It contains phenol, sesamin, sesamol, and sesamolin, all of which contribute to its antioxidant property. The authors investigated the therapeutic effect of oral sesame oil against monocrotaline-induced SOS in rats. <italic>Methods</italic>: Male Sprague-Dawley rats were gavaged with monocrotaline (90 mg/kg) to induce SOS. Control rats were treated with saline only at 0 and 24 hours. Sesame oil (0.5, 1, 2, or 4 mL/kg, orally) was given 24 hours after monocrotaline in rats. Blood samples were collected at 24 and 48 hours after monocrotaline was given to assess the level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Histopathology was also assessed 48 hours after monocrotaline was given. <italic>Results</italic>: AST and ALT were significantly higher in monocrotaline-treated rats than in control rats. Oral sesame oil did not decrease AST and ALT in monocrotaline-treated rats. In addition, liver pathology revealed that oral sesame oil had no therapeutic effect against SOS. <italic>Conclusion</italic>: Oral sesame oil is therapeutically ineffectual against monocrotaline-induced SOS.</p>
</abstract>
<kwd-group>
<kwd>liver</kwd>
<kwd>monocrotaline</kwd>
<kwd>sinusoidal obstruction syndrome</kwd>
<kwd>sesame oil</kwd>
<kwd>rat</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607112445795">
<title>Clinical Relevancy Statement</title>
<p>Therapeutic intervention of subcutaneous sesamol attenuates liver injury and improves metabolic function in monocrotaline-induced sinusoidal obstruction syndrome (SOS) in rats. However, therapeutic oral sesame oil is ineffectual against monocrotaline-induced SOS. Oral sesame oil may increase the burden to the damaged liver after the initiation of SOS, and it shows no therapeutic effect against SOS in rats. The findings warn against using sesame oil as a therapeutic medication and/or nutrition supplement to treat accidental dietary ingestion of pyrrolizidine alkaloids and the cytotoxic drugs cyclophosphamide and busulfan, all of which may cause SOS in patients.</p>
</sec>
<sec id="section2-0148607112445795" sec-type="intro">
<title>Introduction</title>
<p>Severe sinusoidal obstruction syndrome (SOS) represents a life-threatening complication of dose-intensive chemotherapy.<sup><xref ref-type="bibr" rid="bibr1-0148607112445795">1</xref></sup> Oxaliplatin, an anticancer drug for advanced colorectal cancer, has been associated with SOS.<sup><xref ref-type="bibr" rid="bibr2-0148607112445795">2</xref></sup> Oxaliplatin-induced SOS is referred to as blue liver syndrome.<sup><xref ref-type="bibr" rid="bibr3-0148607112445795">3</xref></sup> Dietary ingestion of pyrrolizidine alkaloids (PAs) and cytotoxic drugs also causes SOS.<sup><xref ref-type="bibr" rid="bibr4-0148607112445795">4</xref></sup> Humans have been exposed to PAs through consumption of food grains contaminated with seeds of PA-containing plants. This has led to epidemics of liver disease in India, Afghanistan, and Russia.<sup><xref ref-type="bibr" rid="bibr5-0148607112445795">5</xref></sup> In the United States, exposure occurs through consumption of herbal teas and medicines that contain components of PA-containing plants.<sup><xref ref-type="bibr" rid="bibr5-0148607112445795">5</xref>,<xref ref-type="bibr" rid="bibr6-0148607112445795">6</xref></sup></p>
<p>The monocrotaline-induced rat SOS model is analogous to oxaliplatin-induced blue liver syndrome in humans. SOS is characterized by elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and hepatic injury.<sup><xref ref-type="bibr" rid="bibr7-0148607112445795">7</xref></sup> Monocrotaline initiates its action within 12 hours of administration and prompts sinusoidal endothelial cells (SECs) to get rounded up. Blood penetrates the sinusoidal lining beneath these rounded-up SECs between 24 and 48 hours. The sinusoids are obstructed by embolism of sinusoidal lining cells.<sup><xref ref-type="bibr" rid="bibr8-0148607112445795">8</xref>,<xref ref-type="bibr" rid="bibr9-0148607112445795">9</xref></sup> When rounding up of SECs is prevented, the subsequent development of SOS is averted.<sup><xref ref-type="bibr" rid="bibr9-0148607112445795">9</xref></sup></p>
<p>Sesame oil is a component of traditional health food in various Asian countries. It is effective against various diseases, including atherosclerosis and hypertension, and has antiaging effects.<sup><xref ref-type="bibr" rid="bibr10-0148607112445795">10</xref><xref ref-type="bibr" rid="bibr11-0148607112445795"/>-<xref ref-type="bibr" rid="bibr12-0148607112445795">12</xref></sup> Sesame oil contains a good amount of phenol, sesamin, sesamol, and sesamolin, all of which contribute to its superior antioxidative properties.<sup><xref ref-type="bibr" rid="bibr13-0148607112445795">13</xref></sup> Sesame oil, in comparison to other dietary oils, ground nut oil, and sunflower oil, offers better protection against increased blood pressure, hyperlipidemia, and lipid peroxidation by increasing enzymatic and nonenzymatic antioxidants.<sup><xref ref-type="bibr" rid="bibr14-0148607112445795">14</xref></sup> However, the scientific basis underlying therapeutic oral sesame oil against SOS is not well understood. Thus, we investigated the therapeutic effect of oral sesame oil on monoctotaline-induced SOS in rats.</p>
</sec>
<sec id="section3-0148607112445795" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section4-0148607112445795">
<title>Animals</title>
<p>Male Sprague-Dawley rats 7–8 weeks of age and weighing 250 ± 50 g were purchased from our Institutional Laboratory Animal Center and used in this study. They were given pellet feed (Richmond Standard; PMI Feeds, Inc, St Louis, MO) and water ad libitum. They had a 12-hour light/dark cycle and central air conditioning (25°C, 70% humidity) throughout the experimental period. The animal care and experimental protocols were in accordance with nationally approved guidelines.</p>
</sec>
<sec id="section5-0148607112445795">
<title>Chemicals</title>
<p>Monocrotaline was purchased from Sigma Aldrich (St Louis, MO). To prepare a solution of monocrotaline at 10 mg/mL, 500 mg monocrotaline was dissolved in 1.0 N HCl, and the pH was adjusted to 7.4 with 0.5 N NaOH phosphate-buffered saline (PBS) (pH 7.4), which was added to increase the total volume to 50 mL.<sup><xref ref-type="bibr" rid="bibr7-0148607112445795">7</xref></sup> All other agents were purchased from Sigma.</p>
</sec>
<sec id="section6-0148607112445795">
<title>Experimental Protocol</title>
<p>Monocrotaline-treated rats were used as an experimental model of SOS; this approach has previously been reported to be a reproducible model of SOS.<sup><xref ref-type="bibr" rid="bibr15-0148607112445795">15</xref></sup> The rats were fasted 12 hours before monocrotaline treatment, but they were allowed water ad libitum. Monocrotaline (90 mg/kg) was administered by gavage, and the rats were then allowed food and water ad libitum.</p>
</sec>
<sec id="section7-0148607112445795">
<title>Experimental Design</title>
<p>The rats were divided into 6 groups (n = 6 each). Group I was untreated healthy controls, group II received only oral monocrotaline (90 mg/kg), and groups III, IV, V, and VI received oral monocrotaline (90 mg/kg) and 24 hours later received sesame oil (0.5, 1, 2, and 4 mL/kg, respectively). After 24 and 48 hours, AST and ALT activity was assessed in rat serum. After 48 hours, we harvested a small piece of liver tissue from each rat for histopathological examination.</p>
</sec>
<sec id="section8-0148607112445795">
<title>Collecting Blood</title>
<p>Blood was collected in serum separation tubes from a tail vein at 24 hours and femoral vein puncture at 48 hours while the rats were under mild ether anesthesia. The tubes were left at room temperature for 30 minutes to clot and then centrifuged at 1000 <italic>g</italic> at 4°C for 10 minutes.</p>
</sec>
<sec id="section9-0148607112445795">
<title>Assessing SOS</title>
<p>We assessed hepatic injury by measuring the levels of AST and ALT in serum using a biochemistry analyzer (Fujifilm Dri-Chem 3500s; Fujifilm, Kanagawa, Japan). Hepatic injury was further confirmed using histological studies. A small piece of liver tissue from each rat was cut and placed in 4% phosphate-buffered formalin. The tissue pieces were dehydrated using a graded percentage of alcohol and then fixed in paraffin wax for 1 hour to form blocks. The blocks were trimmed and cut into 4-µm-thick sections, stained with hematoxylin and eosin, and then mounted using Depex-Polystyrene dissolved in xylene mountant. The permanently mounted sections of liver tissue were examined under a microscope (Eclipse E 600; Nikon Instech Co, Ltd, Kawasaki, Japan; magnification, ×40) to assess hepatic injury.</p>
</sec>
<sec id="section10-0148607112445795">
<title>Statistical Analysis</title>
<p>Statistical analysis was performed using SPSS version 11.0.1 software (SPSS, Inc, an IBM Company, Chicago, IL). Data are expressed as the means ± SD. Differences in the measured variables between each group were assessed using a least significant difference test. <italic>P</italic> &lt;.05 was considered to indicate statistical signiﬁcance.</p>
</sec>
</sec>
<sec id="section11-0148607112445795" sec-type="results">
<title>Results</title>
<sec id="section12-0148607112445795">
<title>Therapeutic Effect of Oral Sesame Oil on Hepatic Dysfunction in SOS Rats</title>
<p>Serum AST (<xref ref-type="fig" rid="fig1-0148607112445795">Figure 1A</xref>) and ALT (<xref ref-type="fig" rid="fig2-0148607112445795">Figure 2A</xref>) were significantly higher (<italic>P</italic> &lt; .05) in groups II–VI than in group I after monocrotaline-induced SOS for 24 hours. Sesame oil had no effect on serum AST (<xref ref-type="fig" rid="fig1-0148607112445795">Fig. 1B</xref>) and ALT (<xref ref-type="fig" rid="fig2-0148607112445795">Fig. 2B</xref>) in groups III–VI compared with group II after monocrotaline-induced SOS for 48 hours.</p>
<fig id="fig1-0148607112445795" position="float">
<label>Figure 1.</label>
<caption>
<p>Effect of sesame oil on aspartate aminotransferase (AST) in monocrotaline-treated rats. (A) AST after 24 hours of monocrotaline alone and (B) AST after 48 hours of monocrotaline with sesame oil. Data are means ± SD. Statistical significance: *<italic>P</italic> &lt; .05 vs group I.</p>
</caption>
<graphic xlink:href="10.1177_0148607112445795-fig1.tif"/>
</fig>
<fig id="fig2-0148607112445795" position="float">
<label>Figure 2.</label>
<caption>
<p>Effect of sesame oil on alanine aminotransferase (ALT) in monocrotaline-treated rats. (A) ALT after 24 hours of monocrotaline alone and (B) ALT after 48 hours of monocrotaline with sesame oil. Data are means ± SD. Statistical significance: *<italic>P</italic> &lt; .05 vs group I.</p>
</caption>
<graphic xlink:href="10.1177_0148607112445795-fig2.tif"/>
</fig>
</sec>
<sec id="section13-0148607112445795">
<title>Therapeutic Effect of Sesame Oil on Hepatic Injury in SOS Rats</title>
<p>Liver histopathology from group II showed severe hepatic necrosis with rounding up of SECs, congestion, sinusoidal alteration, destruction of sinusoidal lining, and severe hemorrhage. Sesame oil (groups III–VI) had no therapeutic effect on monocrotaline-induced SOS (group II) rats (<xref ref-type="fig" rid="fig3-0148607112445795">Figure 3</xref>).</p>
<fig id="fig3-0148607112445795" position="float">
<label>Figure 3.</label>
<caption>
<p>Effect of sesame oil on liver pathology in monocrotaline-treated rats. Hematoxylin and eosin staining; photomicrographs were taken at ×40 magnification.</p>
</caption>
<graphic xlink:href="10.1177_0148607112445795-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section14-0148607112445795" sec-type="discussion">
<title>Discussion</title>
<p>Oral sesame oil was therapeutically ineffectual against monocrotaline-induced SOS in rats. Monocrotaline initiated its hemorrhagic and necrotic damage, which is consistent with previous reports.<sup><xref ref-type="bibr" rid="bibr8-0148607112445795">8</xref>,<xref ref-type="bibr" rid="bibr9-0148607112445795">9</xref></sup> Liver pathology revealed central vein endothelial damage, sinusoidal hemorrhage, and coagulative necrosis, all of which confirmed the therapeutic inefficiency of oral sesame oil against SOS. Monocrotaline is also known to induce steatohepatitis.<sup><xref ref-type="bibr" rid="bibr16-0148607112445795">16</xref></sup> In addition, dietary fat with polyunsaturated fatty acid contributes to steatohepatitis.<sup><xref ref-type="bibr" rid="bibr17-0148607112445795">17</xref></sup> Oral sesame oil may increase the burden to the damaged liver after monocrotaline-induced SOS and shows no therapeutic effect.</p>
<p>In our recent finding,<sup><xref ref-type="bibr" rid="bibr18-0148607112445795">18</xref></sup> therapeutic subcutaneous sesamol significantly decreased hepatic injury, and its anti–matrix metalloproteinase (MMP-9) property may have been responsible for its therapeutic action against experimental SOS.<sup><xref ref-type="bibr" rid="bibr18-0148607112445795">18</xref></sup> In the present study, therapeutic oral sesame oil had no effect on hepatic injury, and histopathology revealed fewer sections with severe alterations than in monocrotaline-treated animals. This may be because the therapeutic sesame oil was administered orally, which takes much longer for all of its active components such as sesamol to be absorbed by portal circulation and then metabolized in the liver. However, subcutaneous sesamol is easily absorbed and is more quickly metabolized, biologically active, and available than sesame oil is.<sup><xref ref-type="bibr" rid="bibr19-0148607112445795">19</xref><xref ref-type="bibr" rid="bibr20-0148607112445795"/><xref ref-type="bibr" rid="bibr21-0148607112445795"/>-<xref ref-type="bibr" rid="bibr22-0148607112445795">22</xref></sup></p>
<p>Hepatic metabolism of monocrotaline<sup><xref ref-type="bibr" rid="bibr23-0148607112445795">23</xref></sup> and fatty acids<sup><xref ref-type="bibr" rid="bibr24-0148607112445795">24</xref>,<xref ref-type="bibr" rid="bibr25-0148607112445795">25</xref></sup> requires cytochrome P450 isozymes. Hepatic cytochromes P450s are exploited by monocrotaline for its activation. Therefore, the metabolism of oral sesame oil 24 hours after monocrotaline intake might be considerably decreased. In addition, monocrotaline-induced circulatory changes cause SOS rather than other liver injury.<sup><xref ref-type="bibr" rid="bibr8-0148607112445795">8</xref></sup> Oral sesame oil might have a negative effect on hepatic circulation in SOS-associated liver injury. A potential intervention to attenuate SOS is the early sequence of events that leads to the obstruction of the circulation.<sup><xref ref-type="bibr" rid="bibr9-0148607112445795">9</xref></sup> However, oral sesame oil’s therapeutic intervention was in the late sequence (24–48 hours) of SOS, which might be the reason for its ineffectiveness against SOS. Therefore, we conclude that oral sesame oil is therapeutically ineffectual due to declined metabolism and obstructed circulation in liver.</p>
<p>The clinical implication of the present study is that sesame oil would not have the potential to act therapeutically against SOS in patients undergoing oxaliplatin-based chemotherapy, which causes SOS.<sup><xref ref-type="bibr" rid="bibr2-0148607112445795">2</xref></sup> Various chemicals and antibody conjugates are used in the clinical management of SOS in humans as protective and therapeutic options. They are defibrotide, methylprednisolone, gemtuzumab ozogamicin, danaparoid, and bevacizumab.<sup><xref ref-type="bibr" rid="bibr26-0148607112445795">26</xref><xref ref-type="bibr" rid="bibr27-0148607112445795"/><xref ref-type="bibr" rid="bibr28-0148607112445795"/><xref ref-type="bibr" rid="bibr29-0148607112445795"/><xref ref-type="bibr" rid="bibr30-0148607112445795"/><xref ref-type="bibr" rid="bibr31-0148607112445795"/><xref ref-type="bibr" rid="bibr32-0148607112445795"/>-<xref ref-type="bibr" rid="bibr33-0148607112445795">33</xref></sup> However, they cause numerous adverse effects in patients with cancer. Therefore, we tested the therapeutic action of oral sesame oil against SOS. Although therapeutic subcutaneous sesamol significantly decreases hepatic injury in experimental SOS,<sup><xref ref-type="bibr" rid="bibr18-0148607112445795">18</xref></sup> oral sesame oil as a therapeutic medication and nutrition supplement against accidental dietary ingestion of PAs and chemotherapeutic drugs would be ineffective and might increase the liver injury. We therefore conclude that oral sesame oil may not be a therapeutic option for the treatment of SOS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This research was supported by NSC 99-2314-B-006-031-MY3 and NSC 99-2221-E-006-064-MY3 from the Taiwan National Science Council.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112445795">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>V</given-names></name>
<name><surname>Sgouros</surname><given-names>J</given-names></name>
<name><surname>Smithson</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report</article-title>. <source>J Med Case Reports</source>. <year>2008</year>;<volume>2</volume>:<fpage>227</fpage>.</citation>
</ref>
<ref id="bibr2-0148607112445795">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name>
<name><surname>Audard</surname><given-names>V</given-names></name>
<name><surname>Sartoretti</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer</article-title>. <source>Ann Oncol</source>. <year>2004</year>;<volume>15</volume>:<fpage>460</fpage>-<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112445795">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bilchik</surname><given-names>AJ</given-names></name>
<name><surname>Poston</surname><given-names>G</given-names></name>
<name><surname>Curley</surname><given-names>SA</given-names></name><etal/>
</person-group>. <article-title>Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>: <fpage>9073</fpage>-<lpage>9078</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112445795">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deleve</surname><given-names>LD</given-names></name>
</person-group>. <article-title>Hepatic microvasculature in liver injury</article-title>. <source>Semin Liver Dis</source>. <year>2007</year>;<volume>27</volume>:<fpage>390</fpage>-<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112445795">
<label>5.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Huxtable</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Human health implications of pyrrolizidine alkaloids and herbs containing them</article-title>. In: <person-group person-group-type="editor">
<name><surname>Cheeke</surname><given-names>PR</given-names></name>
</person-group>, ed. <source>Toxicants of Plant Origin</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>; <volume>1989</volume>:<fpage>41</fpage>-<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112445795">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schultze</surname><given-names>AE</given-names></name>
<name><surname>Roth</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Chronic pulmonary hypertension/the monocrotaline model and involvement of the hemostatic system</article-title>. <source>J Toxicol Environ Health</source>. <year>1998</year>;<volume>1</volume>:<fpage>271</fpage>-<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112445795">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narita</surname><given-names>M</given-names></name>
<name><surname>Hatano</surname><given-names>E</given-names></name>
<name><surname>Tamaki</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2009</year>;<volume>24</volume>:<fpage>1051</fpage>-<lpage>1057</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112445795">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deleve</surname><given-names>LD</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Tsai</surname><given-names>J</given-names></name>
<name><surname>Kanel</surname><given-names>G</given-names></name>
<name><surname>Strasberg</surname><given-names>S</given-names></name>
<name><surname>Tokes</surname><given-names>ZA</given-names></name>
</person-group>. <article-title>Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition</article-title>. <source>Gastroenterology</source>. <year>2003</year>;<volume>125</volume>:<fpage>882</fpage>-<lpage>890</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112445795">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DeLeve</surname><given-names>LD</given-names></name>
<name><surname>Ito</surname><given-names>I</given-names></name>
<name><surname>Bethea</surname><given-names>NW</given-names></name>
<name><surname>Mc Cuskey</surname><given-names>MK</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>McCuskey</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Embolization by sinusoidal lining cell obstructs the microcirculation in rat sinusoidal obstruction syndrome (hepatic venooclusive disease)</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2003</year>;<volume>284</volume>:<fpage>G1045</fpage>-<lpage>G1052</lpage>.</citation>
</ref>
<ref id="bibr10-0148607112445795">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fukuda</surname><given-names>Y</given-names></name>
<name><surname>Osawa</surname><given-names>T</given-names></name>
<name><surname>Namiki</surname><given-names>M</given-names></name>
<name><surname>Ozaki</surname><given-names>T</given-names></name>
</person-group>. <article-title>Studies on antioxidative substances in sesame seed</article-title>. <source>Agric Biol Chem</source>. <year>1985</year>;<volume>49</volume>:<fpage>301</fpage>-<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112445795">
<label>11.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Fukuda</surname><given-names>Y</given-names></name>
<name><surname>Osawa</surname><given-names>T</given-names></name>
<name><surname>Namiki</surname><given-names>M</given-names></name>
</person-group>. <article-title>Chemistry of lignan antioxidants in sesame seed and oil</article-title>. In: <person-group person-group-type="editor">
<name><surname>Ho</surname><given-names>CT</given-names></name>
<name><surname>Osawa</surname><given-names>T</given-names></name>
<name><surname>Huang</surname><given-names>MT</given-names></name>
</person-group> eds. <source>Food Phytochemicals for Cancer Prevention II: Teas, Spices and Herbs</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Chemical Society</publisher-name>; <year>1994</year>;<volume>547</volume>:<fpage>264</fpage>-<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112445795">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Namiki</surname><given-names>M</given-names></name>
</person-group>. <article-title>The chemistry and physiological function of sesame</article-title>. <source>Food Reviews Int</source>. <year>1995</year>;<volume>11</volume>:<fpage>281</fpage>-<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112445795">
<label>13.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Fatty acids in oil seeds</article-title>. In: <source>Fatty Acids in Foods and Their Health Applications</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Marcel Dekker</publisher-name>; <volume>1992</volume>:<fpage>237</fpage>-<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112445795">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sankar</surname><given-names>D</given-names></name>
<name><surname>Sambandam</surname><given-names>G</given-names></name>
<name><surname>Rao Ramakrishna</surname><given-names>M</given-names></name>
<name><surname>Pugalendi</surname><given-names>KV</given-names></name>
</person-group>. <article-title>Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils</article-title>. <source>Clin Chim Acta</source>. <year>2005</year>;<volume>355</volume>:<fpage>97</fpage>-<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112445795">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DeLeve</surname><given-names>LD</given-names></name>
<name><surname>McCuskey</surname><given-names>RS</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name><etal/>
</person-group>. <article-title>Characterization of a reproducible rat model of hepatic veno-occlusive disease</article-title>. <source>Hepatology</source>. <year>1999</year>;<volume>29</volume>:<fpage>1779</fpage>-<lpage>1791</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112445795">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baybutt</surname><given-names>RC</given-names></name>
<name><surname>Rosales</surname><given-names>C</given-names></name>
<name><surname>Brady</surname><given-names>H</given-names></name>
<name><surname>Molteni</surname><given-names>A</given-names></name>
</person-group>. <article-title>Dietary fish oil protects against lung and liver inflammation and fibrosis in monocrotaline treated rats</article-title>. <source>Toxicology</source>. <year>2002</year>;<volume>175</volume>:<fpage>1</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112445795">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>GS</given-names></name>
<name><surname>Yan</surname><given-names>JS</given-names></name>
<name><surname>Ng</surname><given-names>RK</given-names></name>
<name><surname>Kakar</surname><given-names>S</given-names></name>
<name><surname>Maher</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury</article-title>. <source>J Lipid Res</source>. <year>2007</year>;<volume>48</volume>:<fpage>1885</fpage>-<lpage>1896</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112445795">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Periasamy</surname><given-names>S</given-names></name>
<name><surname>Hsu</surname><given-names>DZ</given-names></name>
<name><surname>Chen</surname><given-names>SY</given-names></name>
<name><surname>Yang</surname><given-names>SS</given-names></name>
<name><surname>Chandrasekaran</surname><given-names>VR</given-names></name>
<name><surname>Liu</surname><given-names>MY</given-names></name>
</person-group>. <article-title>Therapeutic sesamol attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats by inhibiting matrix metalloproteinase-9</article-title>. <source>Cell Biochem Biophys</source>. <year>2011</year>;<volume>61</volume>:<fpage>327</fpage>-<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr19-0148607112445795">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jan</surname><given-names>KC</given-names></name>
<name><surname>Ho</surname><given-names>CT</given-names></name>
<name><surname>Hwang</surname><given-names>LS</given-names></name>
</person-group>. <article-title>Bioavailability and tissue distribution of sesamol in rat</article-title>. <source>J Agric Food Chem</source>. <year>2008</year>;<volume>56</volume>:<fpage>7032</fpage>-<lpage>7037</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112445795">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>DZ</given-names></name>
<name><surname>Chen</surname><given-names>KT</given-names></name>
<name><surname>Chien</surname><given-names>SP</given-names></name><etal/>
</person-group>. <article-title>Sesame oil attenuates acute iron-induced lipid peroxidation-associated hepatic damage in mice</article-title>. <source>Shock</source>. <year>2006</year>;<volume>26</volume>:<fpage>625</fpage>-<lpage>630</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112445795">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>DZ</given-names></name>
<name><surname>Chu</surname><given-names>PY</given-names></name>
<name><surname>Liu</surname><given-names>MY</given-names></name>
</person-group>. <article-title>Effect of sesame oil on acidified ethanol-induced gastric mucosal injury in rats</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>:<fpage>423</fpage>-<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112445795">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chandrasekaran</surname><given-names>VR</given-names></name>
<name><surname>Wan</surname><given-names>CH</given-names></name>
<name><surname>Liu</surname><given-names>LL</given-names></name>
<name><surname>Hsu</surname><given-names>DZ</given-names></name>
<name><surname>Liu</surname><given-names>MY</given-names></name>
</person-group>. <article-title>Effect of sesame oil against acetaminophen-induced acute oxidative hepatic damage in rats</article-title>. <source>Shock</source>. <year>2008</year>;<volume>30</volume>:<fpage>217</fpage>-<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112445795">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mingatto</surname><given-names>FE</given-names></name>
<name><surname>Maioli</surname><given-names>MA</given-names></name>
<name><surname>Bracht</surname><given-names>A</given-names></name>
<name><surname>Ishii-Iwamoto</surname><given-names>EL</given-names></name>
</person-group>. <article-title>Effects of monocrotaline on energy metabolism in the rat liver</article-title>. <source>Toxicol Lett</source>. <year>2008</year>;<volume>182</volume>: <fpage>115</fpage>-<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr24-0148607112445795">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mast</surname><given-names>N</given-names></name>
<name><surname>Shafaati</surname><given-names>M</given-names></name>
<name><surname>Zaman</surname><given-names>W</given-names></name><etal/>
</person-group>. <article-title>Marked variability in hepatic expression of cytochromes CYP7A1 and CYP27A1 as compared to cerebral CYP46A1: lessons from a dietary study with omega 3 fatty acids in hamsters</article-title>. <source>Biochim Biophys Acta</source>. <year>2010</year>;<volume>1801</volume>:<fpage>674</fpage>-<lpage>681</lpage>.</citation>
</ref>
<ref id="bibr25-0148607112445795">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>C</given-names></name>
<name><surname>Markovic</surname><given-names>M</given-names></name>
<name><surname>Blossey</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids</article-title>. <source>J Biol Chem</source>. <year>2010</year>;<volume>285</volume>:<fpage>32720</fpage>-<lpage>32733</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112445795">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shah</surname><given-names>MS</given-names></name>
<name><surname>Jeevangi</surname><given-names>NK</given-names></name>
<name><surname>Joshi</surname><given-names>A</given-names></name>
<name><surname>Khattry</surname><given-names>N</given-names></name>
</person-group>. <article-title>Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide</article-title>. <source>J Cancer Res Ther</source>. <year>2009</year>;<volume>5</volume>:<fpage>312</fpage>-<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr27-0148607112445795">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>PG</given-names></name>
<name><surname>Soiffer</surname><given-names>RJ</given-names></name>
<name><surname>Antin</surname><given-names>JH</given-names></name><etal/>
</person-group>. <article-title>Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial</article-title>. <source>Biol Blood Marrow Transplant</source>. <year>2010</year>;<volume>16</volume>:<fpage>1005</fpage>-<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112445795">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>IL</given-names></name>
<name><surname>Yang</surname><given-names>SN</given-names></name>
<name><surname>Hsiao</surname><given-names>CC</given-names></name>
<name><surname>Wu</surname><given-names>KS</given-names></name>
<name><surname>Sheen</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Treatment with high-dose methylprednisolone for hepatic veno-occlusive disease in a child with rhabdomyosarcoma</article-title>. <source>Pediatr Neonatol</source>. <year>2008</year>;<volume>49</volume>:<fpage>141</fpage>-<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr29-0148607112445795">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al Beihany</surname><given-names>A</given-names></name>
<name><surname>Al Omar</surname><given-names>H</given-names></name>
<name><surname>Sahovic</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone</article-title>. <source>Bone Marrow Transplant</source>. <year>2008</year>;<volume>41</volume>:<fpage>287</fpage>-<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112445795">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chevallier</surname><given-names>P</given-names></name>
<name><surname>Prebet</surname><given-names>T</given-names></name>
<name><surname>Turlure</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation</article-title>. <source>Bone Marrow Transplant</source>. <year>2010</year>;<volume>45</volume>: <fpage>165</fpage>-<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr31-0148607112445795">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sakaguchi</surname><given-names>H</given-names></name>
<name><surname>Watanabe</surname><given-names>N</given-names></name>
<name><surname>Muramatsu</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Danaparoid as the prophylaxis for hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation in childhood hematological malignancy</article-title>. <source>Pediatr Blood Cancer</source>. <year>2010</year>;<volume>55</volume>:<fpage>1118</fpage>-<lpage>1125</lpage>.</citation>
</ref>
<ref id="bibr32-0148607112445795">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klinger</surname><given-names>M</given-names></name>
<name><surname>Eipeldauer</surname><given-names>S</given-names></name>
<name><surname>Hacker</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases</article-title>. <source>Eur J Surg Oncol</source>. <year>2009</year>;<volume>35</volume>:<fpage>515</fpage>-<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr33-0148607112445795">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name>
<name><surname>Lauwers</surname><given-names>GY</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis</article-title>. <source>Histopathology</source>. <year>2010</year>;<volume>56</volume>:<fpage>430</fpage>-<lpage>439</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>